Mary Hunt, MD
Obstetrics & Gynecology · Springfield, NJNPI 1497799563
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.8%), food and beverage and education — rather than concentrated in one kind of arrangement. Celularity Inc. accounts for 60.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $917 and has fallen 73.5% since, to $243 in 2025.
Across 62 payments — averaging $32.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Celularity Inc.$1K
- Astellas Pharma US Inc$151
- Mayne Pharma Commercial LLC$78
- AbbVie$77
- Pfizer$52
- Sage Therapeutics, LLC$51
- plus $397 from 15 others
What the payments were for
- Speaking & faculty fees$1,20059%
- Food & beverage$81440%
- Education$281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Celularity Inc. | 12 | $1,237 |
| Astellas Pharma US Inc | 7 | $151 |
| Mayne Pharma Commercial LLC | 7 | $78 |
| AbbVie(2 entities) | 5 | $77 |
| Pfizer | 3 | $52 |
| Sage Therapeutics, LLC | 3 | $51 |
| Coopersurgical, Inc. | 3 | $46 |
| Vertical Pharmaceuticals, LLC | 3 | $41 |
| Bayer | 2 | $35 |
| Gilead | 2 | $34 |
| Organon | 3 | $33 |
| Merck | 2 | $32 |
| AMAG Pharmaceuticals, Inc. | 2 | $28 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Mimedx Group, Inc. | 1 | $21 |
| Mirum Pharmaceuticals, Inc. | 1 | $19 |
| Solventum Corporation | 1 | $19 |
| Millicent US Inc | 1 | $18 |
| Mycovia Pharmaceuticals, Inc. | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Exeltis, USA Inc. | 1 | $15 |
How this compares
$2,041 in reported general payments places this provider in the 75th percentile of 1,242 obstetrics & gynecology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 14 | $2,089 |
| Clobetasol Propionate | 12 | $242 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Springfield
- Khashayar VosoughSpringfield$11K
- Jose PintoSpringfield$9K
- Jennifer AshtonEnglewood$1.5M
- Geoffrey BowersVoorhees$228K
- Neha DeshpandePlainsboro$206K
- Paula JasionowskiVoorhees$193K
- Justin ChuraSwedesboro$179K
- Andrea VentolaFlorham Park$145K
- Aiman ShiladPaterson$100K
- Patrick CulliganMorristown$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.